About Us

Archives






ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or…

Posted: July 5, 2021 at 1:51 am


-- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET

Originally posted here:
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or...

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.